Similar articles

• [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2005 Apr 25;147 Spec No 1:54-5. MMW Fortschr Med. 2005. PMID: 16385876 German. No abstract available.
• Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.

  Hill A, Sawyer W. Hill A, et al. HIV Med. 2009 Oct;10(9):527-35. doi: 10.1111/j.1468-1293.2009.00724.x. HIV Med. 2009. PMID: 19785663 Review.
• [Long-term virus suppression. Expanding therapy options with protease inhibitor].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2005 Apr 25;147 Spec No 1:68-9. MMW Fortschr Med. 2005. PMID: 16385882 German. No abstract available.
• Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.

  Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group. Prosperi MC, et al. J Med Virol. 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927. J Med Virol. 2010. PMID: 20981785
• Toxicity of antiretroviral therapy and implications for drug development.

  Carr A. Carr A. Nat Rev Drug Discov. 2003 Aug;2(8):624-34. doi: 10.1038/nrd1151. Nat Rev Drug Discov. 2003. PMID: 12904812 Review. No abstract available.